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age of time spent in target range (TTR) is predictive of
better clinical outcomes. However, strategies to improve
TTR can be costly. To allow local clinical policy makers
to determine whether these strategies can be justiﬁed, we
developed a general approach to estimating bleeding and
TE rates associated with a given population distribution
of INR. 
METHODS: We used data from a large cohort 
(Cannegieter, 1995) to derive a logistic equation for base-
line absolute risk of bleeding as a function of INR. Based
upon a separate large cohort of patients (Fihn, 1993) with
various time since initiation of therapy we derived a risk
ratio that modiﬁes the above baseline relationship in
order to take into account time since initiation of therapy.
A similar strategy was used to estimate TE, using INR
and indication (mechanical valve versus atrial ﬁbrillation)
as predictors.
RESULTS: The model for bleeding was: logit (p) = -8.84
+.83 INR +.64 EARLY, where EARLY = 1 if the patient
is in the ﬁrst 3 months of anticoagulation, and 0 other-
wise. The ﬁnal model for TE was: logit (p) = -73 - 1.17
INR - .64(AF), where AF = 1 if the indication is atrial
ﬁbrillation and 0 if the indication is mechanical heart
valve. The integral of these logistic equations, weighted
by a given population distribution of INR, provides 
population estimates of annual bleed and TE rates. 
CONCLUSION: Existing epidemiological data can
provide tailored estimates of concrete beneﬁts resulting
from improving the quality of anticoagulation.
PCV6
IMPACT OF PHARMACIST-MANAGED
AMBULATORY LIPID CLINIC
Cross LB
University of Tennessee Health Sciences Center, Memphis,TN,
USA
Coronary heart disease (CHD) is the leading cause of
adult deaths in America. Multiple trials have shown that
by modifying cholesterol levels, risk of CHD can be
decreased.
OBJECTIVES: Objectives of this research were to assess
the impact of a pharmacist-managed ambulatory lipid
clinic (PMALC) on CHD-risk proﬁle, effectiveness and
cost of care in patients with hyperlipidemia in a VA
ambulatory clinic. 
METHODS: This longitudinal research began with a 
retrospective review of 30 randomly selected charts using
indicators consistent with NCEP-ATPII guidelines. This
review led to opening the PMALC. After 9 months, 80
randomly selected charts were reviewed (40 PMALC + 40
non-PMALC). To further evaluate the impact of the
PMALC on patient outcomes, researchers took part in a
prospective, randomized, controlled, multi-centered trial.
RESULTS: Initial review suggested that 60% of patients
did not have baseline and follow-up lipid panels, 93% did
not have baseline liver function tests (LFT’s), 55% had
no documented change in LDL after 3 months, 16%
reached LDL goal of <130mg/dL, and 6% reached LDL
goal of <100mg/dL. The second review revealed 100%
of PMALC patients versus 40% of non-PMALC patients
with baseline lipid proﬁles, baseline LFT’s were measured
in 100% of PMALC patients versus 35% of non-PMALC
patients, 66% of PMALC patients reaching an LDL goal
of <130mg/dL versus 36% of non–PMALC patients,
70% of PMALC patients reaching an LDL goal of 
<100mg/dL versus 14% of non—PMALC patients. Non-
PMALC patients utilized more medication, costing
$62/month versus PMALC patients $38/month.
CONCLUSIONS: Pharmacist-managed ambulatory lipid
clinic programs ensured more patients were treated to
NCEP ATP-II guideline goals, offered a cost-effective
option for treating patients, and decreased patients’
overall CHD risk proﬁle versus standard care from
primary care teams.
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Recent studies have shown that reductions in cholesterol
levels among patients with coronary heart disease (CHD)
reduce mortality.
OBJECTIVE: To determine screening rates for hyperlipi-
demia among health plan members recently hospitalized
for CHD. 
METHODS: Utilizing data from a large managed care
company in a major metropolitan area, member data
were selected from the health plan pharmacy, medical and
labs claims databases from April 1, 1998 to April 1, 2000.
Selection criteria included an age of 35 years and older,
continuous enrollment in the plan for the previous 24
months, having one or more inpatient claim during
November 1, 1998 to November 1, 1999 indicating
CHD, and not having a pharmacy claim for a cholesterol
lowering medication within 6 months prior to 
hospitalization.
RESULTS: Of the 74,097 plan members enrolled during
the study period, 340 members met inclusion criteria. Of
these only 7 (2.1%) had prescription claims for a lipid
lowering medications within six months prior to the
admission date and were eliminated from the analysis.
The mean age of the remaining 333 members was 57.6
years (range 35–79). A majority (61.6%, n = 205) of
members were male. A total of 436 lab tests for any 
cholesterol lab value, including total cholesterol, LDL
cholesterol, HDL cholesterol and triglycerides, were com-
pleted for only 66 (19.8%) of 333 members. The mean
number of lab tests for these members was 6.6 (Range 4
to 24).
CONCLUSIONS: The major ﬁnding of this analysis was
the low percentage of members who received any choles-
terol lab test following a hospital admission for CHD.
This suggests that the majority of these high-risk patients
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are not receiving appropriate follow-up care. The cause
of these low screening rates should be examined in future
research.
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OBJECTIVE: This study evaluated the effects of 
pharmacist-managed anticoagulation monitoring services
on the clinical and economic outcomes of patients pre-
scribed warfarin therapy. 
METHODS: A retrospective chart review was conducted
for patients newly initiated with warfarin therapy
between November 1997 and April 1998. Patients used
warfarin for a minimum of 2 months and were followed
for either one-year post-initiation of warfarin usage or
until discontinuation of warfarin therapy, whichever was
earlier. Comparisons were made between the group of
patients receiving anticoagulation monitoring through
usual medical care (UMC) by their physician (“UMC
group”) and those patients enrolled in the pharmacist-
managed anticoagulation clinic (“AC patients”).
Outcome measures for the two groups include anticoag-
ulation control, incidence of warfarin adverse effects or
recurrent thromboembolic disorder, and economic evalu-
ation for inpatient and outpatient health care services 
utilized.
RESULTS: Complete data for 63 UMC patients (625
patient-months) and 18 AC patients (232 patient-months)
indicate that AC patients had better anticoagulation
control than UMC patients (51% of INRs within target
range versus 41%, respectively). However, AC patients
experienced more frequent minor recurrences (events not
requiring hospitalization) of thromboembolic disorders
or bleeding associated with warfarin (0.11 events per 
AC patient-month versus 0.08 events per UMC patient-
month). The incidence of complications that necessitated
hospitalization was similar between the two groups. The
estimated annual inpatient cost of treating the complica-
tions associated with anticoagulant therapy was $168 less
per AC patient but equivalent for both groups for out-
patient services ($348 annually). Inpatient and outpatient
charges for all medical claims for AC patients were less
than half that found for UMC patients ($241 and $405
per patient-month versus $501 and $878 per patient-
month, respectively). 
CONCLUSION: Although treatment-related complica-
tions can still occur, pharmacist-managed anticoagulation
monitoring services provided a better means of main-
taining anticoagulation control and reducing medical care
costs for patients on warfarin therapy.
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OBJECTIVES: Type 2 diabetics with combined hyper-
lipidemia are at increased risk of developing coronary
heart disease (CHD). Fibrates have been shown to
improve lipid parameters; thereby, decreasing CHD risk
among treated patients. We compare fenoﬁbrate to gem-
ﬁbrozil treatment of combined hyperlipidemia in type 2
diabetics by determining the following: one year absolute
and relative risk reductions in CHD, Number Needed to
Treat (NNT) to prevent one case of CHD, and number
of CHD cases prevented. 
METHODS: In patients with lipid parameters consistent
with type 2 diabetes, absolute risk (AR) of developing
CHD in one year was determined using the Anderson car-
diovascular risk equation. Relative risk (RR) comparing
no treatment to treatment and NNT were calculated. 
The number of CHD cases prevented in one year was 
calculated from NNT and prevalence characteristics of 
a 500,000 member Medicaid population. Sensitivity
analyses were performed on age, smoking status, drug
dose, and time horizon.
RESULTS: Base case patients (60 year-old female, non-
smoker) treated with fenoﬁbrate (AR = 1.1, RR = 1.92,
NNT = 97) had lower absolute risks, more favorable 
relative risks comparing no treatment to treatment, and
required treatment of fewer patients to prevent one case
of CHD compared to gemﬁbrozil (AR = 1.5, RR = 1.42,
NNT = 157). In one year, in patients >50 years, 91 CHD
cases were prevented through the model with fenoﬁbrate
treatment, compared to 56 cases prevented with gemﬁ-
brozil. Each sensitivity analysis showed fenoﬁbrate had
the more favorable AR, RR, and NNT. For example,
using a ﬁve year time horizon on a 70 year-old smoking
male, fenoﬁbrate’s AR = 17.8, RR = 1.41, and NNT =
14, while with gemﬁbrozil’s AR = 21.0, RR = 1.20, 
and NNT = 24. In ﬁve years, 348 cases of CHD were 
prevented with fenoﬁbrate compared to 206 with 
gemﬁbrozil.
CONCLUSIONS: Fenoﬁbrate proves a better healthcare
value than gemﬁbrozil due to its superior risk reduction
and prevention of more cases of CHD.
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